Research and Markets has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview
- Therapeutics Development
- Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
- Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
- Aeolus Pharmaceuticals, Inc.
- Angion Biomedica Corp.
- Atox Bio Inc.
- Avaxia Biologics, Inc.
- Bolder Biotechnology, Inc.
- Caladrius Biosciences, Inc.
- Cellerant Therapeutics, Inc.
- Cellphire, Inc.
- Chrysalis BioTherapeutics, Inc.
- Cleveland BioLabs, Inc.
- Cumberland Pharmaceuticals, Inc.
- Diffusion Pharmaceuticals Inc.
- Eli Lilly and Company
- GNI Group Ltd.
- Humanetics Corporation
- INSYS Therapeutics, Inc.
- Meabco A/S
- Neumedicines Inc.
- Onconova Therapeutics, Inc.
- PharmaIN Corporation
- Pluristem Therapeutics Inc.
- ProCertus BioPharm Inc.
- RDD Pharma Ltd.
- RedHill Biopharma Ltd.
- RxBio, Inc.
- Soligenix, Inc.
- Stemedica Cell Technologies, Inc.
- Terapio Corporation
- Tonix Pharmaceuticals Holding Corp.
For more information visit http://www.researchandmarkets.com/research/96vxrd/radiation
View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005706/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals
